Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B
Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics.
The Indianapolis drug giant and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
